Is abnormal non-high-density lipoprotein cholesterol a gender-specific predictor for metabolic syndrome in patients with schizophrenia taking second-generation antipsychotics?
| Autor: | Miaofen Yen, Wen Chuan Shao, Ru Band Lu, Sheng-Yu Lee, Hsin Ju Yang, Esther Ching-lan Lin, Pei Chun Wu |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Adult
Male China medicine.medical_specialty Neurology Hypercholesterolemia Population Psychological intervention Comorbidity Weight Gain Logistic regression Biochemistry Cellular and Molecular Neuroscience Sex Factors Risk Factors Internal medicine Prevalence medicine Humans Psychiatric hospital Psychiatry education Metabolic Syndrome education.field_of_study Anthropometry business.industry Middle Aged medicine.disease Cholesterol Cross-Sectional Studies Schizophrenia Cohort Female Neurology (clinical) Metabolic syndrome business Antipsychotic Agents |
| Zdroj: | Metabolic Brain Disease. 30:107-113 |
| ISSN: | 1573-7365 0885-7490 |
| Popis: | Evidence supports an association between metabolic syndrome (MetS) and schizophrenia. However, specific risk factors for MetS and gender differences in patients with schizophrenia taking second-generation antipsychotics (SGAs) have not been well explored. A cross-sectional cohort of 329 Han Chinese patients was recruited in a psychiatric hospital in central Taiwan. Using the definitions of the International Diabetes Federation for Chinese, the prevalence of MetS was 23.7 % (men: 25.7 %; women: 21.2 %). Logistic regression analyses showed that patients with a BMI ≥ 24 and an abnormal non-high-density lipoprotein cholesterol (non-HDL-C) were significantly (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink